Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Palonosetron Hydrochloride Patent Expiration

Palonosetron Hydrochloride is Used for preventing nausea and vomiting caused by chemotherapy and postoperative procedures. It was first introduced by Helsinn Healthcare Sa in its drug Aloxi on Jul 25, 2003. Other drugs containing Palonosetron Hydrochloride are Posfrea, Palonosetron Hydrochloride. 19 different companies have introduced drugs containing Palonosetron Hydrochloride.


Palonosetron Hydrochloride Patents

Given below is the list of patents protecting Palonosetron Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Aloxi US7947724

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US7947725

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US7960424

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8518981

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8598218

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8598219

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8729094

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9066980

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9125905

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9173942

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9439854

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9457020

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9457021

(Pediatric)

 Liquid pharmaceutical formulations of palonosetron Jul 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US7947724 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US7947725 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US7960424 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8518981 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8598218 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8598219 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US8729094 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9066980 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9125905 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9173942 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9439854 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9457020 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US9457021 Liquid pharmaceutical formulations of palonosetron Jan 30, 2024

(Expired)

 Helsinn Hlthcare
Aloxi US5202333

(Pediatric)

 Tricyclic 5-HT3 receptor antagonists Oct 13, 2015

(Expired)

 Helsinn Hlthcare
Aloxi US5202333 Tricyclic 5-HT3 receptor antagonists Apr 13, 2015

(Expired)

 Helsinn Hlthcare



Palonosetron Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Palonosetron Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Palonosetron Hydrochloride. The first generic version for Palonosetron Hydrochloride was by Sandoz Inc and was approved on Oct 13, 2015. And the latest generic version is by Meitheal Pharmaceuticals Inc and was approved on Aug 14, 2023.

Given below is the list of companies who have filed for Palonosetron Hydrochloride generic, along with the locations of their manufacturing plants worldwide.


1. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A Mar 15, 2021





2. AVET LIFESCIENCES

Avet Lifesciences Ltd has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Avet Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Jun 29, 2021
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

(reference standard)

injectable Prescription INTRAVENOUS N/A Jun 29, 2021





3. BAXTER HLTHCARE CORP

Baxter Healthcare Corp has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Nov 12, 2021





4. CHARTWELL RX

Chartwell Rx Sciences Llc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Chartwell Rx.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Sep 19, 2018





5. CIPLA

Cipla Ltd has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A Sep 19, 2018


Manufacturing Plant Locations
New

Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.

Country City Firm Name
India
Mumbai Cipla Limited
Bangalore Cipla Ltd.
Kurkumbh Village, Dist. Pune Cipla, Ltd.
Pithampur, District Dhar Cipla Limited
Bengaluru Cipla Limited
Raigad Cipla Limited
Vasco Da Gama Cipla Limited





6. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

(reference standard)

injectable Prescription INTRAVENOUS AP Apr 21, 2016
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A Apr 21, 2016





7. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Nov 6, 2018


Manufacturing Plant Locations
New

Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.

Country City Firm Name
India
Medchal-Malkajgiri District EUGIA Pharma Specialities Limited
Riico Industrial Area EUGIA Pharma Specialities Limited
Pashamylaram Eugia Pharma Specialities Limited





8. FRESENIUS KABI USA

Fresenius Kabi Usa Llc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Sep 19, 2018


Manufacturing Plant Locations
New

Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.

Country City Firm Name
United States
Lake Zurich Fresenius Kabi USA, LLC
Grand Island Fresenius Kabi USA, LLC
Skokie Fresenius Kabi USA LLC
North Andover Fresenius Kabi USA, LLC
Wilson Fresenius Kabi USA, LLC
Bensenville Fresenius Kabi USA LLC (FK USA)
Melrose Park Fresenius Kabi USA, LLC
Melrose Park Fresenius Kabi USA LLC





9. HOSPIRA

Hospira Inc has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Hospira.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Sep 19, 2018
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A Sep 19, 2018


Manufacturing Plant Locations
New

Hospira's manufacturing plants are situated in 3 countries - Australia, United States, Dominican Republic (the). Given below are the details of these plant locations as well as the firm names of Hospira as present at those locations.

Country City Firm Name
Australia
Mulgrave Hospira Australia Pty Ltd.
United States
Pleasant Prairie Hospira Worldwide, LLC d.b.a. Hospira, a Pfizer-owned Company
Clayton Hospira, Inc.
Lake Forest Hospira Inc
Morgan Hill Hospira Inc
Mcpherson Hospira, Inc., A Pfizer Company
Rocky Mount Hospira, Inc.
Dominican Republic (the)
Haina, San Cristobal Hospira, Ltd.





10. MEITHEAL

Meitheal Pharmaceuticals Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Meitheal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Aug 14, 2023





11. MYLAN INSTITUTIONAL

Mylan Institutional Llc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Mylan Institutional.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Sep 19, 2018


Manufacturing Plant Locations
New

Mylan Institutional's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Mylan Institutional as present at those locations.

Country City Firm Name
United States
Rockford Mylan Institutional, Inc.





12. NOVAST LABS

Novast Laboratories Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Novast Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A May 22, 2020





13. QILU PHARM HAINAN

Qilu Pharmaceutical Hainan Co Ltd has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Qilu Pharm Hainan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Sep 19, 2018
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A Sep 19, 2018





14. SAGENT PHARMS INC

Sagent Pharmaceuticals Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Sep 19, 2018





15. SANDOZ

Sandoz Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Oct 13, 2015


Manufacturing Plant Locations
New

Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.

Country City Firm Name
Austria
Kundl Sandoz GmbH
Langkampfen Sandoz GmbH
United States
Princeton Sandoz Inc
East Hanover Sandoz Incorporated
Spain
Palafolls Sandoz Industrial Products, S.A.
Les Franqueses Del Valles Sandoz Industrial Products S.A.
India
Navi Mumbai Sandoz Private Limited





16. TEVA PHARMS USA

Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

injectable Discontinued INTRAVENOUS N/A Mar 23, 2018
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

injectable Prescription INTRAVENOUS AP Mar 23, 2018